Abaxis Inc. (NASDAQ:ABAX) shares traded up 2.2% during trading on Monday . The company traded as high as $47.94 and last traded at $47.38, with a volume of 167,070 shares changing hands. The stock had previously closed at $46.36.

A number of research analysts recently commented on the stock. Zacks Investment Research downgraded shares of Abaxis from a “hold” rating to a “sell” rating in a research report on Monday. Canaccord Genuity dropped their target price on shares of Abaxis from $47.00 to $42.00 and set a “hold” rating on the stock in a research report on Friday, April 1st. Feltl & Co. downgraded shares of Abaxis from a “hold” rating to a “sell” rating in a research report on Friday, July 22nd. CL King assumed coverage on shares of Abaxis in a research report on Friday, April 1st. They issued a “neutral” rating on the stock. Finally, TheStreet upgraded shares of Abaxis from a “hold” rating to a “buy” rating in a research note on Thursday, June 9th. Four equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $45.30.

The company has a 50 day moving average price of $48.30 and a 200 day moving average price of $45.30. The stock has a market capitalization of $1.11 billion and a price-to-earnings ratio of 35.83.

Abaxis (NASDAQ:ABAX) last released its quarterly earnings results on Thursday, July 21st. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.32 by $0.02. During the same period in the prior year, the company earned $0.31 EPS. The firm had revenue of $57.70 million for the quarter, compared to analyst estimates of $58.70 million. Analysts predict that Abaxis Inc. will post $1.38 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 15th. Stockholders of record on Thursday, September 1st will be given a dividend of $0.12 per share. The ex-dividend date is Tuesday, August 30th. This represents a $0.48 annualized dividend and a dividend yield of 0.98%.

In related news, Director Richard Bastiani sold 5,000 shares of the company’s stock in a transaction dated Thursday, June 9th. The shares were sold at an average price of $46.75, for a total value of $233,750.00. Following the completion of the sale, the director now owns 54,400 shares of the company’s stock, valued at $2,543,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Henk Evenhuis sold 3,000 shares of the company’s stock in a transaction dated Monday, May 9th. The stock was sold at an average price of $45.00, for a total transaction of $135,000.00. Following the completion of the sale, the director now directly owns 15,400 shares of the company’s stock, valued at approximately $693,000. The disclosure for this sale can be found here.

A number of large investors recently bought and sold shares of ABAX. Principal Financial Group Inc. increased its stake in Abaxis by 4.0% in the fourth quarter. Principal Financial Group Inc. now owns 145,758 shares of the company’s stock valued at $8,116,000 after buying an additional 5,638 shares during the last quarter. Deere & Co. increased its stake in Abaxis by 349.9% in the fourth quarter. Deere & Co. now owns 41,045 shares of the company’s stock valued at $2,285,000 after buying an additional 31,921 shares during the last quarter. New York State Common Retirement Fund increased its stake in Abaxis by 0.4% in the fourth quarter. New York State Common Retirement Fund now owns 494,365 shares of the company’s stock valued at $27,526,000 after buying an additional 2,000 shares during the last quarter. Rhumbline Advisers increased its stake in Abaxis by 1.4% in the fourth quarter. Rhumbline Advisers now owns 45,742 shares of the company’s stock valued at $2,547,000 after buying an additional 625 shares during the last quarter. Finally, Morgan Stanley increased its stake in Abaxis by 28.2% in the fourth quarter. Morgan Stanley now owns 29,523 shares of the company’s stock valued at $1,643,000 after buying an additional 6,489 shares during the last quarter.

Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.